A phase I trial of azacitidine and nanoparticle albumin bound paclitaxel in patients with advanced or metastatic solid tumors | Zendy

Adam L. Cohen | Zendy; Abhijit Ray | Zendy; Matthew Van Brocklin | Zendy; David Burnett | Zendy; Randy C. Bowen | Zendy; Donna Lynn Dyess | Zendy; Thomas W. Butler | Zendy; Theresa Dumlao | Zendy; Hung T. Khong | Zendy

Open Access

A phase I trial of azacitidine and nanoparticle albumin bound paclitaxel in patients with advanced or metastatic solid tumors

Author(s) -

Adam L. Cohen,

Abhijit Ray,

Matthew Van Brocklin,

David Burnett,

Randy C. Bowen,

Donna Lynn Dyess,

Thomas W. Butler,

Theresa Dumlao,

Hung T. Khong

Publication year - 2016

Publication title -

oncotarget

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.373

H-Index - 127

ISSN - 1949-2553

DOI - 10.18632/oncotarget.14183

Subject(s) - medicine , paclitaxel , cancer , oncology , salt lake , paleontology , structural basin , biology

Secreted protein acidic and rich in cysteine (SPARC), an albumin-binding protein, is downregulated by hypermethylation in many cancers. Hypomethylating agents such as azacitidine can upregulate SPARC in tumors, which may enhance the accumulation of albumin-bound drugs at tumor site. The objectives of this phase I trial was to determine the safety and maximum tolerated dose and to assess any clinical activity of the combination of azacytidine and weekly nanoparticle-albumin-bound (nab®) paclitaxel.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research